The guidelines provide recommendations for the treatment of colorectal tumors based on KRAS mutations regarding left-sided tumors, while less clear to date are the recommendations concerning the right colon KRAS BRAF WT, in which chemotherapy (double or triple) + the association with anti-VEGF remains the cornerstone of the treatment. The gene discussed is KRAS; the disease is colorectal neoplasm.